Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sickle Cell Disease Male or female patients ages ≥ 18 years 2. Confirmed diagnosis of homozygous SS or S-β0Thalassemia 3. Intolerance to hydroxyurea therapy, refusal of hydroxyurea therapy, or failure to respond (refractoriness) to hydroxyurea therapy, either clinically or hematologically. 4. Clinically significant sickle cell disease as defined by: 1. At least two hospitalizations over the past twelve months for any complication of sickle cell disease; or 2. At least three pain crises over the past twelve months that last four or more hours and require a visit to a medical facility for treatment with oral or parenteral narcotics; or 3. History of recurrent leg ulcers; or 4. History of Acute Chest Syndrome within the past five years; or 5. History of priapism requiring medical intervention within the past two years; or 6. History of stroke (but not currently on a chronic blood transfusion regimen). 5. Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. 6. Clinically euthyroid. Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism  Use of agents that can induce Hb F within 60 days of Day 1 (i.e. hydroxyurea, butyrates, decitabine, 5-azacytidine, IMiDs®, or erythropoietin). Prior use of HDACi, including panobinostat, is not an criterion if discontinued > 60 days. 2. Patients who have had a vaso-occlusive crisis within the past 2 weeks that required treatment with parenteral medication. 3. Impairment of GI function or GI disease that may significantly alter the absorption of panobinostat (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) 4. Patients on a chronic transfusion regimen, or any patient who has Hb A% > 20% from a recent transfusion 5. Any of the following laboratory abnormalities derived from the screening visit Absolute neutrophil count (ANC) < 1.5 x 109/L Hemoglobin < 6 g/dl Platelets < 100x 109/L Serum creatinine >1.5 x Upper limits of normal (ULN) AST and ALT > 2.5 x ULN Serum total bilirubin > 10 mg/dL Serum direct bilirubin > 1 mg/dL Albumin <3.0 g/dl Serum potassium < Lower limits of normal (LLN)